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The prevalence of hepatitis B virus (HBV) infection in patients with haematological malignancies is higher than that in the general population. [1] The higher prevalence can be explained by the immune suppression induced by cytotoxic chemotherapy, which leads to increased susceptibility. [2, 3] Immune suppression may also lead to reactivation of occult HBV infection and increased HBV replication.
Horizontal transmission of HBV during early childhood is consid ered the main route of infection in developing countries.
[49] This transmission of HBV is unrelated to sexual, perinatal or parenteral exposure. Transmission between family members may occur in communities with poor socioeconomic and hygienic conditions, and with long periods of close interaction. [10] The mode of horizontal transmission is uncertain, but contact with body fluids, mainly saliva, is a prominent feature. [7, 8, 11] Vaccination is recommended for individuals at risk of HBV infection as a result of percutaneous or mucosal exposure to blood or blood products, as well as for those at risk of severe hepatitis B infection. [5] Patients in oncology units, transplant candidates, and individuals receiving frequent blood or blood product transfusions should be vaccinated. [1, 5] From April 1995, the HBV vaccine was included in the South African Expanded Programme of Immunisation (EPISA) at 6, 10 and 14 weeks of age. No 'catchup' immunisation of older age groups was implemented. [4] In 2010, 94% of children in South Africa (SA) were reported to be fully immunised against HBV (received three doses) in their first year of life. [6, 8] However, according to the World Health Organization (WHO), only 56% of babies in SA received all three doses. [8] Current reports on children vaccinated against HBV in SA have found a low prevalence of hepatitis B surface antigen (HBsAg) positivity, ranging from none in children with unknown HIV status to 2.7% in HIVpositive children. [8, 9] The effectiveness of the HBV vaccine is assessed by measuring antibody levels to HBsAg (antiHBs) levels in the serum. Various studies conducted after the inclusion of HBV vaccine in the EPI SA immunisation schedule have shown the vaccine to be highly immunogenic and effective. [8] Protective levels of antiHBs, defined as >10 mIU/l in healthy, immunecompetent children, [8] were found in 78 87% of healthy children, with none or very few children positive for HBsAg or HBV DNA. The vaccine was also tested in babies with HIV infection, in whom it has proved to be less effective. For example, protective levels of antiHBs achieved through immunisation were found in 78.1% of HIVpositive patients in comparison with 85.7% of HIVnegative patients. [8] The duration of HBVvaccineinduced immunity after primary immunisation during infancy is not known. [12, 13] Although specific antibody levels decline rapidly after vaccination, protection through immune memory is thought to extend into adulthood. The waning of vaccineinduced immunity could leave adolescents and adults at risk of HBV infection. [13] 
Objective
This study reports on an audit of records of children presenting to a haematology and oncology unit. Our primary objective was to investigate serological evidence of previous exposure to HBV or vaccine immunity to HBV at first presentation. A secondary objective was to identify patients at risk of contracting hepatitis B infection Background. Hepatitis B is an important public health concern in South Africa (SA). The hepatitis B virus (HBV) vaccine was introduced into the South African Expanded Programme on Immunisation (EPISA) in 1995. There is no 'catchup' programme in place. The duration of protection after hepatitis B vaccination in the SA population is unknown. Waning of vaccineinduced immunity leaves people at risk of acquiring hepatitis B infection in settings where the prevalence of infection is high and horizontal transmission is likely. Objective. To assess immunity to HBV in patients at presentation to a paediatric haematology and oncology unit.
Methods. An audit of hepatitis profiles was done of all new patients seen in the unit from January 2012 to December 2013. Patients were classified as immune (antibody levels to hepatitis B surface antigen (antiHBs) >100 mIU/ml), low immune (antiHBs 10 100 mIU/ml) and not immune (antiHBs <10 mIU/ml). Results. Of the 210 patients included (median age 6.5 years), 84 (40.0%) had no immunity to hepatitis B despite presumed vaccination as part of the EPI schedule. Six patients tested positive for hepatitis B core antibody (antiHBc), consistent with previous infection. No patients had active hepatitis B infection (hepatitis B surface antigenpositive). Most human immunodeficiency virus (HIV)infected patients were not immune to HBV (80.0%). Conclusion. A significant number of children in SA are not immune to hepatitis B despite vaccination being part of the EPISA. Combined passiveactive immunisation should be considered for all oncology patients in settings where exposure to HBV is possible. Consideration should also be given to offering booster vaccination to the population as a whole.
September 2014, Vol. 104, No. 9 through horizontal transmission. The overall aim of the study was to provide a basis on which a further preventive strategy could be developed if deemed necessary.
Methods
A hospitalbased audit was done using patient records of all children who presented to the paediatric haematology and oncology unit at Steve Biko Academic Hospital (SBAH), a tertiary academic hospital in Pretoria, SA, during the period 1 January 2012 31 December 2013. Demographic data (age and gender) and diagnosis of each patient were documented on presentation. HBV serology results for all patients (irrespective of the diagnosis) were reviewed.
Serological screening for hepatitis A, B and C is routinely done on all new patients on presentation to the unit. Screening for HBV includes serological testing for HBsAg, antiHBs and antibodies to hepatitis B core antigen (antiHBc). Hepatitis B eantigen (HBeAg) and antibodies to hepatitis B eantigen (antiHBe) are only tested for when HBsAg is positive (in patients with hepa titis B infection). Immunoassays using Abbott ARCHITECT i2000 (Abbott Diagnostics, Germany) were used for HBV sero logical testing.
AntiHBs levels of >100 mIU/ml were defined as complete protection against hep atitis B infection, levels of 10 100 mIU/ml as partial protection and levels of <10 mIU/ml as no protection. Antibody levels of >100 mIU/ ml are recommended for ensuring protection against hepatitis B infection in immune compromised patients. [1417] Data were analysed with SSPS version 21. All proportions are reported as per centages with 95% confidence intervals (CIs). Differences between proportions were com pared using the χ 2 test. A threshold of significance of p=0.05 was used for all analyses.
Results
A total of 210 patients who presented to our unit between 1 January 2012 and 31
December 2013 were included. None had received previous immunosuppressive therapy. were HIVinfected, and of these eight (32.0%) were newly diagnosed on presentation to the unit. There were 130 boys and 80 girls in the study group. The median age of the study group as a whole was 6.5 years (range 3 weeks 17.6 years), that of the leukaemia/ lymphoma group 7.3 years (range 4 weeks 16.7 years), that of the solid tumour group 4.9 years (range 3 weeks 17.6 years), and that of the group with benign or nonmalignant haematological conditions 7.9 years (range 3 weeks 15.7 years).
Active hepatitis B infection (HBsAg) was not detected in any of the patients during screening at the time of presentation to the unit. Six patients (2.9%) had evidence of previous infection with antiHBc detected in serum, but no current active infection (HBsAgnegative). One of the six patients with evidence of previous infection was HIVpositive and not yet on antiretroviral treatment.
Of the 210 patients in the study, 84 (40.0%; 95% CI 33.3 47.0) were sero negative for HBV, and 78 (37.1%; 95% CI 30.6 44.0) had antiHBs titres of 10 100 mIU/ml, considered to be insufficient in a population of immunecompromised patients. Only 48 patients (22.9%; 95% CI 17.4 29.2%) had antiHBs titres >100 mIU/ml and were therefore protected against acquiring HBV (Fig. 1 ). Of the 25 HIVpositive patients, 20 (80.0%; 95% CI 59.3 93.2) had no immun ity to HBV (antiHBs titres <10 mIU/ml) (Fig. 2 ). There was a significant difference in immunity against HBV between the 1 5years age group and the over12 age group (p=0.005). In the age group 1 5 years, 26 of 71 patients (36.6%; 95% CI 25.5 48.9) had sufficient immunity (antiHBs titres >100 mIU/ml), while in the over12 age group only four of 40 (10.0%; 95% CI 2.8 23.7) did so. In the <1year age group, five infants were <8 weeks of age and had therefore not received the first dose of HBV vaccine and had no protective immunity.
In the group with benign or non malignant haematological conditions, 12 of the 46 patients (26%; 95% CI 14.2 41.0) had antiHBs levels of >100 mIU/ml, and in the leukaemia/lymphoma group only nine of 72 patients (12.5%; 95% CI 5.9 22.4) did so (Fig. 3 ).
Discussion
None of the patients in this study had active hepatitis B infection at initial screening and only six had evidence of previous infection. This rate of exposure to HBV is in keeping with the prevalence in SA (range 0 2.7%) and reflects the protective effect of the immunisation received as part of the EPISA.
There were, however, a large number of patients (77.1%) in the study with sub optimal antiHBs titres of <100 mIU/ml. While there is no consensus about what level of antibodies against HBV is pro tective in immunecompromised patients, it is accepted that a level of >10 mIU/ml after immunisation decreases the risk of a child with a normal immune response becoming a chronic carrier, despite the declining antibody level.
[1417] The immune memory capable of protecting against chronic or symptomatic hepatitis B infection persists even after antibody levels decline to <10 mIU/ml. [12] This immune memory has been shown to be protective in a large percentage of healthy children, but has not been assessed in patients on immunosuppressive therapy. The defects in immunological functioning caused by intensive chemotherapy may adversely affect the immune memory so that it may not be protective in childhood cancer patients. [18] Despite being vaccinated as part of the EPISA, patients have acquired HBV in the paediatric oncology unit at SBAH. [7] Previous studies have shown that HBV immunity declines with age. [6, 8, 12, 13] We were able to demonstrate a significant difference in levels of immunity to HBV in our patients. However, when comparing the 1 5year age group with the over12 group in this study, this difference in immunity may be overestimated when the size of the study population (N=210) is taken into account. It is not possible to comment on the decline of HBV immunity in the study patients, because their HBV serology was not repeated.
Factors that increase susceptibility to HBV infection and reactivation in paediatric oncology patients may include frequent prolonged hospital admissions, severe immunecompromised states, a need for frequent blood product administration, and destruction of mucous membranes following cytotoxic chemotherapy. [1, 2] Active immunisation against HBV has been shown to be effective in patients with cancer. [3] The role of passive immunisation using a specific immune globulin containing a high titre of antiHBs (HBIG) in combination with hepatitis B vaccine has been well described in the setting of postexposure prophylaxis following perinatal exposure for infants born to HBsAgpositive mothers. [19] HBIG is also used for protection against severe recurrent HBV infection in liver transplant patients. [19] The combination of intravenous HBIG with HBV vaccination in children with malignant diseases has been studied in Poland [20] and India. [21] In both these studies, combined passiveactive immunisation offered better protection against nosocomial HBV infection than active immunisation alone. The cost implication of offering solely passive prophylaxis during intensive chemotherapy of patients with leukaemia and nonHodgkin's lymphoma led to discontinuation of this protocol and a recommendation for simultaneous passive and active immunoprophylaxis from the start of such therapy. [20] HIVpositive patients in this study had very low levels of immunity to HBV. We could find no published reports on immunity to HBV of HIVinfected children compared with HIVnegative children. Among unimmunised adults, patients with AIDS were reported to have significantly decreased antiHBs titres compared with a control group of HIVnegative adults. [22] Adults with HBV/HIV coinfection have significantly higher HBV viral loads and for this reason are highly infectious, with an increased risk of transmitting HBV to close contacts and susceptible health workers. [22] This is especially relevant and dangerous in a paediatric haematology and oncology unit where patients are continuously in close contact with each other and where there have been previous reports of HBV transmission. [7] Patients with underlying HIV disease at the time of cancer diagnosis should be given combined passiveactive immunisation to offer the best possible protection against HBV infection. [23] Acute hepatitis infection caused by HBV could lead to delays in chemotherapy and for this reason worsen the patient's cancer related prognosis. [1] Most children infected with HBV develop chronic hepatitis and therefore have an increased risk of developing cirrhosis and hepatocellular carcinoma. [3] The complications of chronic hepatitis could potentially have a detrimental effect on the longterm morbidity of this group of patients.
Conclusion
A large group of patients attending our paediatric haematology and oncology unit did not have sufficient protective antibodies against HBV at first presentation, despite being vaccinated as part of the EPISA. These patients are at risk of hepatitis B infection. Active surveillance and continued screening for HBV must be done at first presentation of all patients attending a paediatric haema tology and oncology unit, and regularly during treatment and followup. A programme to immunise all seronegative patients against HBV should be implemented, and the response to immunisation documented. The use of combined passiveactive immunisation should be encouraged, especially in children with haematological malignancies and HIVinfected children. Implementation of an effective screening and vaccination programme in the haematology and oncology unit should protect all patients from contracting HBV.
